KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Accumulated Depreciation & Amortization (2017 - 2025)

Amneal Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $606.2 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $606.2 million for Q4 2025, up 7.57% from a year ago — trailing twelve months through Dec 2025 was $606.2 million (up 7.57% YoY), and the annual figure for FY2025 was $606.2 million, up 7.57%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $606.2 million at Amneal Pharmaceuticals, up from $563.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for AMRX hit a ceiling of $606.2 million in Q4 2025 and a floor of $394.6 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $508.0 million (2023), compared with a mean of $503.6 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 18.79% in 2021 and later rose 7.57% in 2025.
  • Amneal Pharmaceuticals' Accumulated Depreciation & Amortization stood at $394.6 million in 2021, then grew by 13.03% to $446.0 million in 2022, then rose by 13.91% to $508.0 million in 2023, then grew by 10.92% to $563.5 million in 2024, then increased by 7.57% to $606.2 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $606.2 million (Q4 2025), $563.5 million (Q4 2024), and $508.0 million (Q4 2023) per Business Quant data.